influenza
perenni
problem
affect
million
peopl
annual
everpres
threat
devast
pandem
activ
prophylaxi
vaccin
influenza
viru
current
main
countermeasur
supplement
antivir
howev
disadvantag
strategi
includ
impact
antigen
drift
necessit
constant
updat
vaccin
strain
composit
emerg
antivir
drug
resist
develop
option
influenza
prophylaxi
particularli
broad
act
agent
abl
provid
protect
period
onset
pandem
develop
strain
specif
vaccin
great
interest
exploit
broadspectrum
mediat
could
provid
barricad
protect
earli
critic
phase
influenza
viru
outbreak
passiv
immun
potenti
provid
immedi
antivir
effect
inhibit
viru
replic
reduc
viru
shed
therebi
protect
vulner
popul
event
impend
influenza
pandem
review
passiv
broadspectrum
influenza
prophylaxi
option
focu
har
natur
host
defens
includ
interferon
antibodi
season
influenza
caus
seriou
diseas
burden
particularli
children
elderli
need
develop
annual
vaccin
base
predict
circul
strain
due
antigen
drift
viru
furthermor
newli
emerg
novel
influenza
virus
pose
signific
threat
pandem
potenti
devast
consequ
moreov
pandem
strain
vaccin
requir
time
develop
deploy
viru
replic
spread
initi
uncheck
allow
outbreak
gain
momentum
current
vaccin
antivir
use
control
influenza
emerg
viru
resist
measur
present
limit
furthermor
antivir
drug
could
stockpil
suffici
amount
global
suppli
altern
control
measur
need
urgent
consid
potenti
solut
lie
develop
univers
vaccin
base
conserv
viral
epitop
induc
crossreact
antibodi
neutral
variant
virus
within
subtyp
protect
heterolog
virus
therefor
whilst
exist
vaccin
inadequ
cross
protect
univers
vaccin
may
difficult
achiev
pertin
time
consid
possibl
broadspectrum
option
particularli
differ
viru
subtyp
previous
experienc
human
emerg
pandem
potenti
review
discuss
broadspectrum
control
option
emphasi
har
power
natur
immun
via
neutral
antibodi
effect
passiv
broadspectrum
protect
earli
phase
epidem
could
provid
barricad
viru
exposur
especi
interv
viru
identif
activ
vaccineinduc
immun
consequ
earli
intervent
passiv
prophylaxi
may
revolution
control
option
influenza
potenti
impact
season
pandem
influenza
prepared
influenza
influenza
b
virus
caus
season
diseas
winter
month
hemispher
death
year
although
natur
anim
reservoir
influenza
virus
aquat
shorebird
high
pathogen
avian
influenza
hpai
virus
influenza
research
treatment
recent
emerg
high
fatal
rate
domest
poultri
speci
cross
human
ha
dual
bind
affin
sialic
acid
receptor
predominantli
found
avian
speci
human
respect
allow
increas
infect
avian
virus
human
respiratori
tract
mortal
rate
hpai
spread
throughout
eurasia
newli
emerg
viru
china
around
respect
report
human
case
infect
present
time
humantohuman
transmiss
virus
rel
rare
confound
factor
avian
influenza
viru
vaccin
develop
includ
genet
engin
viru
better
growth
egg
poorer
immunogen
season
influenza
subtyp
human
need
use
higher
dose
andor
adjuv
improv
efficaci
four
pandem
occur
sinc
start
centuri
sever
occur
due
spanish
flu
pandem
estim
million
death
recent
novel
virus
emerg
caus
pandem
due
natur
reassort
swine
influenza
viru
differ
viru
cocircul
virus
sinc
reassort
virus
construct
laboratori
investig
transmiss
virul
one
viru
possess
ha
gene
deriv
hpai
viru
combin
remain
seven
gene
segment
pandem
viru
display
greater
virul
hpai
potenti
increas
mammalian
transmiss
thu
complac
continu
threat
pandem
new
emerg
pathogen
influenza
virus
increas
mammalian
transmiss
influenza
viru
replic
also
impair
mucociliari
clearanc
increas
suscept
bacteri
superinfect
often
fatal
review
addit
immun
dysfunct
prone
respiratori
diseas
excess
cytokin
stimul
airway
influenza
viru
infect
rapidli
progress
pneumonia
fatal
acut
lung
injuri
thu
effect
strategi
combat
influenza
pandem
catastroph
proport
involv
gener
broadspectrum
immun
protect
immunopatholog
therebi
lower
risk
sever
illnessassoci
complic
reduc
morbid
mortal
current
influenza
control
requir
effect
vaccin
updat
vaccin
strain
match
develop
annual
basi
requir
seed
viru
prepar
gener
either
reassort
revers
genet
propag
egg
cultur
cell
recombin
dna
plasmidbas
viruslik
particl
vaccin
altern
option
current
licens
inactiv
live
attenu
vaccin
coldadapt
temperaturesensit
virus
recombin
protein
heterosubtyp
immun
confer
varieti
experiment
vaccin
includ
extracellular
domain
matrix
protein
formalininactiv
whole
viru
nonetheless
contemporari
vaccin
would
narrow
viru
specif
delay
avail
restrict
capac
meet
global
demand
pandem
situat
univers
influenza
vaccin
target
invari
region
viru
induc
effect
broadli
neutral
immun
respons
could
potenti
provid
effect
antivir
coverag
find
appropri
immunogen
major
issu
intens
investig
limit
efficaci
vaccineinduc
b
cell
respons
conserv
region
ha
viral
protein
gener
low
frequenc
gener
poor
antibodi
respons
neuraminidas
inhibitor
although
potent
inactiv
viru
replic
shown
display
limit
effect
use
beyond
hour
infect
due
high
viral
titr
requir
regular
dose
risk
exposur
viru
outbreak
antivir
besid
na
inhibitor
zanamivir
oseltamivir
block
channel
adamantan
use
howev
prepandem
stockpil
antivir
govern
reconsid
poor
strategi
emerg
viru
resist
review
antivir
develop
target
specif
oligosaccharidecompris
site
envelop
virus
cyanovirin
viral
rna
depend
rna
polymeras
favipiravir
possibl
combin
target
differ
stage
viru
replic
cycl
synergist
therapeut
approach
innov
drug
may
offer
futur
clinic
benefit
includ
mediat
cleavag
sialic
acid
host
glycan
receptor
defensin
antivir
peptid
prevent
virion
entri
ligand
pika
promot
dc
matur
antagonist
eritoran
block
cytokin
cascad
nucleic
acidbas
drug
polyic
cpg
activ
innat
immun
sirna
target
conserv
viral
rna
sequenc
furthermor
envelop
viru
neutral
compound
polyphenol
found
pomegran
juic
green
tea
even
scorpion
venom
peptid
hold
promis
strain
diversityindepend
antivir
activ
innat
ifn
potent
pleiotrop
cytokin
stimul
cell
induc
antivir
state
signal
transduct
pathway
activ
transcript
specif
gene
subset
ifn
molecul
compris
multipl
subtyp
protein
belong
type
ii
iii
famili
play
import
role
earli
host
defens
viru
infect
divers
antivir
immunomodulatori
properti
figur
ifn
best
character
type
ifn
famili
compris
ifn
subtyp
beta
tau
epsilon
omega
mani
howev
influenza
virus
evad
innat
immun
part
nonstructur
ns
protein
target
interferon
regulatori
factor
irf
block
ifn
promot
activ
antagon
endogen
ifn
pathway
type
ifn
subtyp
ifn
ifn
ifn
ifn
ifn
ifninduc
protein
viperin
provid
broadspectrum
protect
influenza
virus
ifn
shown
activ
transcript
ifnstimul
gene
isg
heterogen
antivir
activ
mammalian
cell
major
antivir
state
induc
rnasel
inhibit
viral
nucleic
acid
replic
block
viru
protein
translat
mx
abrog
format
viral
ribonucleoprotein
ifn
also
affect
immun
cell
prolifer
differenti
matur
migrat
surviv
ifn
orchestr
downstream
adapt
immun
respons
activ
b
cell
switch
antibodi
class
secret
stimul
cell
prolifer
surviv
sustain
cell
memori
although
protein
type
ifn
famili
bind
singl
type
cell
surfac
receptor
ifnar
bind
affin
downstream
signal
pathway
differ
result
activ
isg
subset
influenc
viru
cell
type
ifn
use
clinic
therapi
varieti
infect
diseas
although
ifn
therapi
predominantli
util
subtyp
may
less
effect
depend
viru
cell
type
differenti
efficaci
found
individu
ifn
subtyp
mous
model
influenza
subtyp
effect
reduc
lung
influenza
viru
titer
ifnsubtyp
also
shown
protect
drive
pulmonari
type
respons
beyond
day
normal
switch
eosinophilianeutrophilia
natur
infect
ifn
deliveri
often
via
bolu
inject
advers
side
effect
includ
sever
influenzalik
ill
fatigu
depress
intranas
instil
ifn
respiratori
mucosa
protect
suscept
type
ii
alveolar
epitheli
cell
influenza
viru
infect
associ
variou
efficaci
preclin
trial
question
still
need
adequ
address
time
rout
dosag
ifn
regimen
effect
cover
protect
measur
influenza
importantli
exogen
ifn
immunogen
otherwis
neutral
antibodi
respons
develop
render
treatment
ineffect
attempt
overcom
advers
side
effect
current
mode
ifntreat
recent
clinic
trial
investig
administr
lowdos
oral
ifnprophylaxi
undertaken
deem
ineffect
protect
acut
respiratori
ill
influenza
pandem
recent
type
iii
ifnlambda
famili
discov
found
induc
similar
antivir
effect
type
ifn
except
cellrestrict
signal
mainli
epitheli
cell
hepatocyt
although
cytokin
bind
receptor
distinct
type
ifn
cell
bodi
produc
ifn
type
induc
tlr
activ
intern
sensor
rigi
ifn
ifnhav
shown
import
control
influenza
experiment
anim
model
util
doubl
receptor
knockout
mice
paradox
ifn
may
either
reduc
enhanc
inflammatori
condit
repeat
applic
respiratori
tract
need
address
clinic
trial
importantli
unregul
ifn
protein
level
exacerb
lung
inflamm
immunopatholog
regul
ifn
pathway
complex
mediat
receptor
densiti
bind
affin
stat
phosphoryl
multimer
isg
transcript
regulatori
feedback
loop
unless
improv
safeti
regim
util
clinic
studi
use
type
type
iii
ifn
appear
show
limit
potenti
influenza
prophylaxi
unsuit
longterm
protect
respiratori
mucosa
limit
exogen
ifn
product
capac
speciesspecif
ifn
signal
may
disadvantag
pandem
control
stimul
polyclon
b
cell
gener
circul
antibodi
pool
multipl
epitop
reactiv
induc
vaccin
natur
infect
influenza
viru
antibodi
block
bind
viral
ha
protein
cell
surfac
receptor
directli
neutral
viru
prevent
viru
entri
viru
infect
cycl
abrog
humor
immun
respons
spread
viru
neighbor
cell
inhibit
viru
shed
reduc
infect
clear
combin
antibodi
effector
cell
respons
extens
review
elsewher
importantli
product
highli
function
neutral
antibodi
ha
epitop
influenza
virus
even
nomin
level
rel
correl
protect
figur
cognat
signal
secret
factor
activ
helper
cell
also
activ
b
cell
secret
virusspecif
antibodi
extrafollicular
antibodysecret
cell
mainli
produc
earli
igm
regul
type
ifn
cytokin
wherea
inher
innat
host
factor
influenc
matur
b
cell
process
class
switch
produc
igg
cours
influenza
viru
infect
memori
b
cell
antibodysecret
cell
form
germin
center
produc
virusspecif
antibodi
recal
respons
secondari
viru
infect
trival
inactiv
live
attenu
vaccin
predominantli
induc
humor
respons
neutral
antibodi
direct
ha
globular
head
domain
block
specif
viru
bind
thu
inhibit
viru
entri
howev
antibodi
specif
limit
efficaci
variabl
viral
sequenc
due
high
mutat
rate
ha
head
domain
current
renew
interest
passiv
immun
mediat
neutral
antibodi
protect
influenza
convalesc
sera
survivor
spanish
flu
pandem
report
reduc
mortal
rate
convalesc
plasma
treatment
deem
effect
individu
china
pandem
hong
kong
noteworthi
even
rel
low
titr
antiha
antibodi
convalesc
plasma
hai
titer
protect
ferret
fatal
hpai
viru
infect
passiv
transfer
hour
viru
challeng
intranas
deliveri
bovin
igg
obtain
colostrum
found
provid
passiv
prophylaxi
influenza
research
treatment
influenza
mice
specif
antibodi
challeng
viru
strainmatch
broader
efficaci
antibodi
neutral
capac
may
achiev
mixtur
polyclon
antibodi
specif
rais
multival
ha
vaccin
altern
broadli
neutral
antibodi
conserv
region
ha
capabl
neutral
differ
strain
within
subtyp
group
group
type
influenza
virus
may
effect
prophylact
interim
therapi
addit
antihead
ha
antibodi
antistalk
ha
antibodi
shown
block
fusion
promot
antibodydepend
cellular
cytotox
infect
cell
broad
neutral
capac
routin
haemagglutin
inhibit
assay
detect
antistalk
antibodi
discoveri
potenti
hastalkspecif
antibodi
larg
remain
unknown
time
advantag
antiha
head
antibodi
prone
escap
mutat
certain
antistalk
antibodi
less
suscept
mutat
stalk
epitop
membraneproxim
region
critic
viru
function
rather
attempt
directli
induc
broadli
neutral
antibodi
human
vaccin
limit
find
appropri
immunogen
approv
adjuv
antibodi
may
practic
effect
gener
donor
anim
optim
vaccin
protocol
prophylaxi
human
howev
knowledg
protect
coverag
dosag
rout
administr
antibodi
need
gain
investig
monoclon
neutral
antibodi
cross
protect
influenza
viru
strain
recov
human
igm
memori
b
cell
human
monoclon
antibodi
also
identifi
broadspectrum
prophylact
efficaci
hpai
influenza
virus
mice
ferret
memori
past
exposur
influenza
viru
strain
also
appar
heterovari
immun
individu
year
age
rather
younger
pandem
variou
monoclon
igg
antibodi
ha
epitop
investig
broadspectrum
prophylaxi
mice
efficaci
compar
antivir
amantadin
oseltamivir
zanamivir
use
human
chimer
virusspecif
monoclon
antibodi
fab
fragment
explor
recent
year
circumv
immunogen
issu
address
suitabl
antibodi
broadspectrum
passiv
prophylaxi
howev
develop
suppli
may
practic
cost
effect
pandem
control
influenza
furthermor
optim
dose
mode
deliveri
singl
monoclon
antibodi
prepar
stalk
domain
issu
much
higher
titr
need
parenter
deliveri
oppos
intranas
deliveri
polyclon
antibodi
high
affin
target
multipl
epitop
viral
ha
protein
substanti
investig
influenza
control
igg
antibodi
shown
play
major
role
protect
ferret
homolog
heterolog
influenza
virus
mention
select
region
head
stalk
domain
ha
molecul
highli
conserv
induc
cross
protect
antibodi
respons
albeit
suboptim
ha
head
immunodomin
stalk
antigen
rel
low
immunogen
stimul
larg
amount
highli
reactiv
antibodi
classic
vaccin
regim
howev
broadli
neutral
high
affin
antibodi
could
potenti
prepar
anim
immun
manipul
use
modifi
vaccin
regim
better
adjuv
licens
human
use
vaccin
anim
gener
heterolog
polyclon
antibodi
benefit
target
respons
potenti
key
epitop
sinc
preexist
memori
b
cell
specif
immunodomin
epitop
present
outcompet
b
cell
exampl
primeboost
vaccin
strategi
found
increas
neutral
antibodi
titer
reduc
lung
viru
load
log
expand
number
divers
activ
haspecif
cell
clone
although
univers
vaccin
human
ultim
goal
broadli
neutral
antibodi
produc
larg
anim
donor
strateg
vaccin
regim
would
use
interim
therapi
influenza
heterolog
antibodi
could
passiv
administ
intranas
rout
provid
immedi
protect
respiratori
tract
mucosa
intranas
deliveri
broadli
neutral
antibodi
investig
mice
afford
protect
warrant
studi
preclin
model
vaccin
larg
rumin
anim
dairi
cow
current
consid
potenti
suppli
bulk
sourc
milkderiv
neutral
antibodi
clinic
trial
clearli
mani
unansw
question
regard
efficaci
rout
administr
dosag
time
immun
memori
reexposur
need
address
futur
investig
antistalk
ha
antibodybas
prophylaxi
influenza
despit
modern
advanc
vaccin
technolog
avail
antivir
antibiot
improv
global
surveil
influenza
viru
contemporari
pandem
may
wors
case
scenario
occur
compound
factor
civil
unrest
exist
poor
medic
infrastructur
overcrowd
develop
countri
like
epicent
newli
emerg
influenza
viru
outbreak
clearli
intervent
need
earli
effect
robust
effort
curtail
morbid
mortal
figur
antibodybas
passiv
immun
power
prophylact
strategi
influenza
pandem
control
reduc
risk
viru
spread
popul
ideal
antibodybas
therapi
could
selfadminist
via
either
inhal
intranas
spray
protect
coverag
airway
first
wave
pandem
dairi
industri
infrastructur
countri
eg
australia
provid
opportun
bulk
antibodi
product
larg
rumin
one
may
specul
singl
mg
dose
potent
broadli
neutral
antibodi
could
effect
durat
coverag
month
would
requir
dose
possibl
could
distribut
famili
selfadminist
assum
figur
model
impact
prophylaxi
mortal
curv
pandem
influenza
prophylaxi
could
protect
morbid
mortal
rate
lower
number
case
effect
passiv
immun
import
provid
coverag
first
wave
sixmonth
risk
period
pandem
whilst
effect
vaccin
develop
identifi
viru
induc
activ
immun
averag
annual
milk
product
lcow
feasibl
approxim
kg
immunoglobulin
dose
could
produc
per
cow
addit
suscept
high
risk
exposur
immunoprophylaxi
option
would
also
particularli
import
previous
vaccin
season
influenza
may
unrespons
pandem
influenza
vaccin
due
transient
antivir
state
recent
term
innat
imprint
monoclon
antibodybas
immunotherapi
broadli
neutral
capabl
univers
antiinfluenza
vaccin
show
promis
influenza
prophylaxi
afford
protect
respiratori
tract
mucosa
review
interest
polyclon
antibodybas
immunotherapi
recent
reignit
studi
show
neutral
efficaci
antistalk
antibodi
new
mode
action
ferret
model
prospect
produc
bulk
suppli
antibodi
larg
product
anim
present
strateg
approach
like
gener
robust
antibodi
respons
donor
anim
passiv
transfer
directli
induc
natur
viru
infect
current
licens
vaccin
adjuv
use
human
altern
animalbas
product
antibodi
express
therapeut
antibodi
tobacco
plant
also
recent
interest
treatment
current
ebola
viru
outbreak
west
africa
although
scaleup
adequ
suppli
may
limit
preclin
model
investig
intranas
deliveri
rumin
polyclon
antibodi
protect
respiratori
mucosa
mice
infect
influenza
viru
found
exogen
igg
deriv
sheep
model
rumin
protect
mice
upon
viru
challeng
protect
fcindepend
effect
day
viru
exposur
larg
prevent
infect
lung
preserv
normal
lung
architectur
benefit
intranas
administr
direct
noninvas
deliveri
antibodi
lumen
respiratori
mucosa
wherea
natur
influenza
viru
infect
presenc
igg
airway
deriv
circul
antibodi
transud
igm
iga
transport
across
epithelium
lumen
investig
antistalk
antibodi
isotyp
subclass
gener
immun
donor
anim
requir
increas
knowledg
optim
efficaci
cross
protect
clade
span
viru
type
antivir
prevent
strategi
control
newli
emerg
reemerg
influenza
viru
strain
pandem
potenti
utmost
import
whilst
intens
effort
made
meet
urgent
need
univers
vaccin
elicit
longterm
immun
passiv
immunoprophylaxi
would
benefit
immedi
shortterm
protect
especi
benefit
elderli
young
one
poorer
antibodi
respons
vaccin
control
influenza
antivir
drug
lower
risk
complic
drug
resist
develop
adamantan
longer
recommend
use
furthermor
costeffect
manag
low
resourc
set
problemat
mani
endem
region
especi
south
east
asia
broadspectrum
immunoprophylaxi
hold
futur
promis
effect
control
measur
influenza
prepar
broadli
neutral
antibodi
anim
donor
potenti
inexpens
independ
host
immun
memori
influenza
virus
domin
respons
haspecif
memori
b
cell
often
induc
vaccin
natur
infect
phenomenon
first
describ
origin
antigen
sin
conclus
seriou
concern
may
mitig
passiv
immunoprophylaxi
use
broadli
neutral
antibodi
provid
univers
coverag
multipl
influenza
virus
provid
interim
control
option
pandem
influenza
author
declar
conflict
interest
